BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary

Rhea-AI Summary

BioLife Solutions (Nasdaq: BLFS) announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies (f/k/a SAVSU Technologies), to Peli BioThermal for $25.5 million in cash, subject to customary adjustments.

The company said the divestiture will streamline its product portfolio and operations to concentrate resources on high-margin recurring revenue in its core cell and gene therapy tools and services business.

Positive

• $25.5 million cash proceeds from sale
• Divestiture streamlines product portfolio and operations
• Allows focus on high-margin recurring revenue in core CGT tools

Negative

• Sale removes BioLife's owned cold-chain logistics capability
• Transaction proceeds are subject to certain adjustments

BOTHELL, Wash., Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC. (f/k/a SAVSU Technologies, Inc.) ("SAVSU"), its wholly owned cold chain logistics subsidiary, for $25.5 million (subject to certain adjustments) in cash to Peli BioThermal, a global leader in temperature-controlled logistics solutions.

Roderick de Greef, Chairman and CEO commented "This divestiture streamlines our product portfolio as well as our operations while focusing resources on creating shareholder value through high-margin recurring revenue. We are delighted that a respected leader in cold chain logistics recognizes the value of the SAVSU evo technology." 

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "intend," "expects," "continue," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof, or to reflect any change in our expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Media & Investor Relations

At the Company

Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors

Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-announces-the-sale-of-its-evo-cold-chain-logistics-subsidiary-302576396.html

SOURCE BioLife Solutions, Inc.

FAQ

What did BioLife (BLFS) announce on October 7, 2025?

BioLife announced the sale of its wholly owned cold chain subsidiary SAVSU to Peli BioThermal for $25.5 million in cash, subject to adjustments.

How much cash will BioLife (BLFS) receive from the SAVSU sale?

The company will receive $25.5 million in cash from the sale, subject to certain adjustments.

Why is BioLife (BLFS) selling its SAVSU cold chain subsidiary?

BioLife said the divestiture streamlines its portfolio and operations to focus resources on high-margin recurring revenue in its core CGT business.

Who purchased SAVSU from BioLife (BLFS)?

Peli BioThermal, a global temperature-controlled logistics company, purchased SAVSU.

Will the SAVSU sale affect BioLife's core cell and gene therapy business?

BioLife indicated the sale is intended to refocus resources on its core cell and gene therapy tools and services.

Are the sale proceeds final for BioLife (BLFS)?

The announced $25.5 million cash consideration is described as being subject to certain adjustments.